https://www.linkedin.com/jobs/view/2520499798/?refId=zupyq1nfTbibM1rWN7mouw%3D%3D Anyone else not believe in the IPO fairytale? Why would anyone want to invest in a company with an empty pipeline and low growth?
Any company filing for IPO generally does so with a strong pipeline and business plan moving forward. With low growth rates and no innovation Galderma will struggle.
This was EQTs game plan along. They just kept on dropping the ball and are hoping no one noticed. IPO at anytime within the next year will have a difficult time succeeding. Just stating the obvious.
A pipeline drug is not a done deal until it is approved. And even then it can be yanked! To those who are betting on Nemo – its akin to crossing your fingers and hoping that Santa Claus is coming to town. These are same type of people who go to McDonalds and order a Big Mac, Fries and a Diet Coke - thinking the Diet Coke will “help” them in there quest to be less obese
Very unlikely the investment community will even consider Nemo as a valuable asset as it is 3 to 4 years away. What other real pharma company is hyping a drug so far away? Focus will be on Ax and Consumer for the IPO. Pharma is a generic company with very little value to add.
Consumer business could get divested in the next months. Cetaphil is losing ground vs CeraVe. It takes substantial investment to defend this business. There is no innovation in aesthetics and the prescription pipeline is a branded generic one. Not a good starting point for a successful IPO.
Pharmaceutical investors are keen watchers of the three P’s: portfolio, patent and pipelines. Nothing exciting down the line at Galderma.
Why would I, or any institution, invest/gamble on a company that has a potential high share dilution and high failure probability? Might as well move money to the magic money tree of crypto
Which is the reason I doubt their will be an IPO in the next year or two. Best time would be in 2023 when Nemo is closer and Consumer is back to #1 and Aesthics is a billion dollar unit. IPO is all about timing and now is not the time.
I would think any due diligence would reveal what a nightmare situation is developing at Galderma. Investors don't swoop in to change well-oiled machines; they swoop in on operations that aren't running on all cylinders. Our consortium of investors will probably push for change given the low growth. Sale to next Private Equity is more likely then IPO.
Investors: the crew who have been in power for the last 18 months have nearly driven this company to its death, lack experience of the market and how to do their jobs, yet are still running the company? How and why are they still in roles? How do you justify Thomas? Jessica? Alexandre Brennan ans other useless VPs? It has not been a turn around by far and yet we still employ these people?? Need to start explaining this.
I’ve got news for you if you think the PE guys answer to you. Go update that resume and get out if you hate it that much.
EQT needs to fire the CEO & CFO for tanking Galderma. They are rookies who don’t understand the space we’re in.
$10.2bn was the price paid. A realistic valuation was around $7.6bn. Why was such a premium paid? Empty pipeline? Unrealistic sales forecast? Geographical expansion? Whoever buys Galderma next might have to pay $12bn or more. What is the rationale? With no new products and low growth, the numbers don’t stack up. Can someone explain the logic?
I read all the speculation here and you all don't know anything at all. You have no idea how the business is being built with business development and potential new products. So 2021 is a slow year, but the future is bright. How could we have anticipated that Teva would have challenged the Soolantra patent? The Galderma brand still means quality. Say what you will about MS, KC, and others but they are strong managers on a new team that will bring Galderma Rx into the future. If you aren't part of the solution...you are.part.of the problem. If you don't like Galderma then shut up and leave.
